Schonfeld Strategic Advisors LLC Akero Therapeutics, Inc. Transaction History
Schonfeld Strategic Advisors LLC
- $15.4 Billion
- Q4 2024
A detailed history of Schonfeld Strategic Advisors LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 262,295 shares of AKRO stock, worth $11.4 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
262,295
Previous 278,323
5.76%
Holding current value
$11.4 Million
Previous $7.99 Million
8.62%
% of portfolio
0.05%
Previous 0.06%
Shares
12 transactions
Others Institutions Holding AKRO
# of Institutions
210Shares Held
74.3MCall Options Held
321KPut Options Held
558K-
Wellington Management Group LLP Boston, MA7.38MShares$321 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY6.86MShares$299 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$263 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$243 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$228 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.02B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...